No subtype specific MGMT promoter methylation differences were detected in brain metastases deriving from lung (squamous cell carcinoma (3), small cell carcinoma (4), adenocarcinoma (16), large cell carcinoma (1), neuroendocrine tumours (2), poorly differentiated (8), NOS (9)) and breast carcinoma (invasive ductal (9), neuroendocrine tumors (2), mucinous carcinoma (1), poorly differentiated (6), NOS (27)). This evidence concerns the gene MGMT and large cell carcinoma.